This study was initiated to evaluate the efficacy of the peptidyl arginine deiminase (PAD) inhibitor BB-Cl-Amidine (BB-CLA) on canine and feline mammary cancer cell lines in vitro and in vivo. The gene discussed is SELPLG; the disease is breast cancer.